San Francisco, CA – May 22, 2026 – A significant setback has been announced in the pursuit of novel treatments for Parkinson’s disease, as Biogen and Denali Therapeutics have decided to discontinue further development of their investigational drug, BIIB122 (also known as DNL151), for idiopathic Parkinson’s disease. The decision comes after the disappointing results from the Phase IIb LUMA study, which failed to demonstrate a slowing of disease progression compared to a placebo.
The LUMA study, a large-scale, multi-center, global, double-blind, placebo-controlled, and randomized trial, enrolled 648 patients aged between 30 and 80 years who were diagnosed with early-stage Parkinson’s disease. A key aspect of the trial’s design was its inclusivity, allowing participation regardless of whether patients carried a pathogenic LRRK2 variant, a genetic mutation associated with an increased risk of developing Parkinson’s. Patients in the study received either BIIB122 or a placebo for an extended treatment period, ranging from 48 to a remarkable 144 weeks.
While the investigational drug showed promising biological activity, as evidenced by significant inhibition of peripheral LRRK2 kinase and a reduction in a key biomarker of LRRK2 activity in cerebrospinal fluid, it ultimately did not translate into a clinical benefit for the broader Parkinson’s patient population. This outcome marks a significant disappointment for the neuroscience community and the many individuals and families affected by Parkinson’s disease, a progressive neurodegenerative disorder that affects millions worldwide.
The LUMA Study: A Detailed Look at the Clinical Trial
The LUMA study was designed with the primary objective of evaluating whether BIIB122 could alter the course of early-stage Parkinson’s disease. The trial’s primary endpoint was the time to confirmed worsening in a composite score derived from the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II (non-motor experiences of daily living) and III (motor examination). This composite score is a widely accepted measure for assessing disease progression in Parkinson’s patients.
The results, however, were clear: BIIB122 did not demonstrate a statistically significant slowing of disease progression compared to the placebo group. This primary endpoint failure cast a shadow over the study’s objectives. Furthermore, the secondary endpoints, which were designed to assess other potential benefits of the drug, also failed to show any demonstrable advantage of BIIB122 over placebo. This lack of efficacy across multiple outcome measures solidified the decision to halt development for this specific indication.
Despite the clinical disappointment, the LUMA study did yield valuable insights into the drug’s pharmacological profile. Exploratory biomarker analyses revealed that BIIB122 successfully achieved over 90% inhibition of peripheral LRRK2 kinase activity. This is a critical finding, as LRRK2 is a key protein kinase implicated in the pathogenesis of Parkinson’s disease, particularly in individuals with specific genetic mutations. Additionally, a sub-study involving cerebrospinal fluid (CSF) analysis demonstrated a reduction of approximately 30% in phosphorylated Rab10, a well-established biomarker of LRRK2 pathway activity.
Crucially, the study confirmed that target therapeutic levels of BIIB122 in both blood and CSF were consistently maintained throughout the entire trial period. This indicates that the drug was adequately absorbed and distributed within the central nervous system, suggesting that the lack of efficacy was not due to insufficient drug exposure. The safety profile of BIIB122 was also deemed acceptable, with general tolerability observed among participants. This is an important consideration, as any new Parkinson’s treatment must not only be effective but also safe for long-term use.
Chronology of Development and Discontinuation
The journey of BIIB122 began with the recognition of LRRK2’s role in Parkinson’s disease. Biogen, a prominent biotechnology company with a strong focus on neurological disorders, partnered with Denali Therapeutics, a company specializing in neurodegenerative disease therapeutics, to develop this investigational LRRK2 inhibitor.
Pre-Clinical and Early-Stage Development:
- Research into LRRK2 as a therapeutic target for Parkinson’s disease gains momentum.
- Biogen and Denali Therapeutics collaborate on the development of BIIB122 (DNL151), a small molecule inhibitor designed to target LRRK2 kinase activity.
Phase I and IIa Studies:
- Early-phase clinical trials are conducted to assess the safety, tolerability, and pharmacokinetics of BIIB122 in healthy volunteers and potentially in patients with Parkinson’s disease.
- These initial studies likely inform the design of larger, pivotal trials.
Phase IIb LUMA Study Initiation:
- The LUMA study is initiated as a large-scale, multi-center, global, double-blind, placebo-controlled, randomized trial.
- The study aims to evaluate the efficacy and safety of BIIB122 in a broad population of patients with early-stage Parkinson’s disease.
- Enrollment of 648 patients aged 30 to 80 years begins, with treatment durations planned for 48 to 144 weeks.
Study Completion and Data Analysis:
- Patients complete their designated treatment periods.
- Comprehensive data are collected and analyzed, focusing on the primary and secondary endpoints.
Announcement of Discontinuation (May 22, 2026):
- Biogen and Denali Therapeutics announce that the LUMA study did not meet its primary or secondary efficacy endpoints.
- The companies jointly decide to discontinue further development of BIIB122 for idiopathic Parkinson’s disease.
Ongoing Research in Specific Subgroups:
- Denali Therapeutics announces it will continue an independent Phase IIa BEACON study.
- The BEACON study will specifically evaluate BIIB122 in participants who carry a pathogenic LRRK2 variant.
- Results from the BEACON study are anticipated in the first half of 2027, focusing on safety, pharmacokinetics, and biomarkers related to lysosomal pathway engagement in this specific genetic subgroup.
Supporting Data and Biomarker Findings
While the clinical efficacy of BIIB122 for the general Parkinson’s population was not observed, the study’s biomarker data provide valuable insights into the drug’s biological activity. The significant inhibition of peripheral LRRK2 kinase, exceeding 90%, is a strong indicator that BIIB122 effectively engages its intended target in the body. This level of target engagement is often a prerequisite for a drug to exert a therapeutic effect.
The observed reduction in phosphorylated Rab10 in CSF, by approximately 30%, further supports the drug’s mechanism of action. Rab10 phosphorylation is a downstream consequence of LRRK2 kinase activation, and its reduction suggests that BIIB122 is successfully modulating the LRRK2 pathway within the central nervous system. This is particularly relevant as the LRRK2 pathway has been implicated in various cellular processes that are disrupted in Parkinson’s disease, including lysosomal function and protein trafficking.
The consistent achievement of target levels of BIIB122 in both blood and CSF throughout the trial period is also a crucial piece of supporting data. It confirms that the drug can be delivered effectively to the brain at therapeutic concentrations, ruling out pharmacokinetic limitations as a reason for the lack of efficacy. This finding is important for future drug development efforts targeting neurological conditions, as achieving adequate central nervous system exposure can be a significant challenge.
The safety profile of BIIB122, described as acceptable and generally well-tolerated, is another vital piece of supporting information. The absence of significant safety concerns means that the drug could potentially be revisited for other indications or in different patient populations where it might prove effective, provided that further efficacy data emerges.
Official Responses and Perspectives
The announcement of the discontinuation of BIIB122 for idiopathic Parkinson’s disease was met with measured disappointment from the leadership at Biogen. Diana Gallagher, Senior Vice President and Head of Neurodegeneration Clinical Development at Biogen, acknowledged the unfavorable outcome.
"While these are not the results we hoped for, these data provide important information to the Parkinson’s community and will be presented at an upcoming scientific conference," Gallagher stated. Her sentiment highlights the scientific rigor of the process and the commitment to sharing knowledge, even when the outcomes are not as desired. She further expressed profound gratitude, stating, "We are profoundly grateful to the patients, families, and investigators who participated in this study and contributed to our understanding of Parkinson’s disease." This acknowledgment underscores the vital role of participants and researchers in advancing medical knowledge.
The decision to discontinue development for the broader Parkinson’s population does not signal an end to the investigation of BIIB122. Denali Therapeutics has confirmed its commitment to continuing the independent Phase IIa BEACON study. This study is specifically designed to evaluate BIIB122 in participants who carry a pathogenic LRRK2 variant. This targeted approach recognizes that LRRK2-related Parkinson’s disease may represent a distinct subtype where LRRK2 inhibition could potentially be more effective. The BEACON study’s focus on safety, pharmacokinetics, and biomarkers related to lysosomal pathway engagement in this genetic subgroup suggests a renewed hope for a more precise therapeutic application of the drug. Results from the BEACON study are expected in the first half of 2027, offering a potential path forward for BIIB122 in a more defined patient population.
Implications for Parkinson’s Research and Future Treatments
The failure of BIIB122 to demonstrate efficacy in the LUMA study has significant implications for the field of Parkinson’s disease research and the development of future treatments. It underscores the complexity of this heterogeneous disease and the challenges in identifying therapeutic targets that translate into clinical benefits for all affected individuals.
Firstly, the study highlights the critical distinction between pharmacological activity and clinical efficacy. While BIIB122 successfully inhibited the LRRK2 pathway and demonstrated target engagement, this biological effect did not translate into a measurable slowing of disease progression in the broad population studied. This emphasizes the need for robust clinical trial designs and endpoints that accurately reflect meaningful patient outcomes.
Secondly, the decision to continue development in a specific genetic subgroup (LRRK2 variant carriers) suggests a growing trend towards precision medicine in Parkinson’s disease. As our understanding of the genetic underpinnings of the disease evolves, therapies may be increasingly tailored to specific genetic profiles or biological subtypes. This approach could potentially improve the success rates of clinical trials and lead to more effective treatments for select patient populations.
Thirdly, the LUMA study’s findings, while disappointing, contribute valuable data to the scientific community. The detailed information on the drug’s pharmacokinetics, safety profile, and biomarker engagement will inform future research and development efforts, even for other LRRK2 inhibitors or drugs targeting related pathways. The knowledge gained from this large-scale trial will undoubtedly influence the design of subsequent studies in the field.
Finally, this setback serves as a reminder of the urgent need for continued investment and innovation in Parkinson’s disease research. While the path to effective treatments is often arduous, the dedication of researchers, pharmaceutical companies, and, most importantly, patients and their families, remains paramount. The insights gleaned from the LUMA study, though not the outcome hoped for, will contribute to the ongoing quest for a cure or effective disease-modifying therapies for Parkinson’s disease. The scientific community will be keenly awaiting the results from the BEACON study to see if BIIB122 can find its niche in treating a specific subset of this devastating condition.
About the Author
